Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-12-20
2005-12-20
Campell, Bruce R. (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S317000, C530S323000
Reexamination Certificate
active
06977241
ABSTRACT:
Disclosed are compounds for SH2 domain binding inhibition. For example, disclosed is a compound of formula (I)wherein R1is a lipophile; R2, in combination with the phenyl ring, forms a phenylphosphate mimic group or a protected phenylphosphate mimic group; R3is hydrogen, azido, amino, carboxyalkyl, alkoxycarbonylalkyl, aminocarbonylalkyl, or alkylcarbonylamino, wherein the alkyl portion of R3may be optionally substituted with a substituent selected from the group consisting of halo, hydroxy, carboxyl, amino, aminoalkyl, alkyl, alkoxy, and keto; R6is a linker; AA is an amino acid; and n is 1 to 6; or a salt thereof. Also disclosed are a pharmaceutical composition, a method for inhibiting an SH2 domain from binding with a phosphoprotein and a method of treating breast cancer.
REFERENCES:
patent: 3906031 (1975-09-01), Carpino et al.
patent: 4394519 (1983-07-01), Carpino et al.
patent: 4879398 (1989-11-01), Getman et al.
patent: 5182263 (1993-01-01), Danho et al.
patent: 5200546 (1993-04-01), Burke, Jr. et al.
patent: 5272268 (1993-12-01), Toyoda et al.
patent: 5296608 (1994-03-01), Danho et al.
patent: 5369110 (1994-11-01), Schmidlin et al.
patent: 5457114 (1995-10-01), Stüber et al.
patent: 5463062 (1995-10-01), Hemmerle et al.
patent: 5491253 (1996-02-01), Stuk et al.
patent: 5508437 (1996-04-01), Danho et al.
patent: 5521175 (1996-05-01), Castro Pineiro et al.
patent: 5525733 (1996-06-01), Novack et al.
patent: 5580979 (1996-12-01), Bachovchin
patent: 5587372 (1996-12-01), Aszodi et al.
patent: 5612370 (1997-03-01), Atwal
patent: 5616776 (1997-04-01), Stuk et al.
patent: 5618812 (1997-04-01), Castro Pineiro et al.
patent: 5627283 (1997-05-01), Stüber et al.
patent: 5646036 (1997-07-01), Schwall et al.
patent: 5679842 (1997-10-01), Kleiner
patent: 5681833 (1997-10-01), Castro Pineiro et al.
patent: 5686292 (1997-11-01), Schwall et al.
patent: 5688992 (1997-11-01), Burke, Jr. et al.
patent: 5698731 (1997-12-01), Bosetti et al.
patent: 5707624 (1998-01-01), Nickoloff et al.
patent: 5710129 (1998-01-01), Lynch et al.
patent: 5710173 (1998-01-01), Tang et al.
patent: 5712395 (1998-01-01), App et al.
patent: 5753687 (1998-05-01), Mjalli et al.
patent: 5756817 (1998-05-01), Choi et al.
patent: 5773411 (1998-06-01), Wells et al.
patent: 5780496 (1998-07-01), Tang et al.
patent: 5786454 (1998-07-01), Waksman et al.
patent: 5789427 (1998-08-01), Chen et al.
patent: 5792771 (1998-08-01), App et al.
patent: 5792783 (1998-08-01), Tang et al.
patent: 5834504 (1998-11-01), Tang et al.
patent: 5843997 (1998-12-01), Heinz et al.
patent: 5849693 (1998-12-01), Wells et al.
patent: 5849742 (1998-12-01), App et al.
patent: 5880141 (1999-03-01), Tang et al.
patent: 5883110 (1999-03-01), Tang et al.
patent: 5883113 (1999-03-01), Tang et al.
patent: 5883116 (1999-03-01), Tang et al.
patent: 5886020 (1999-03-01), Tang et al.
patent: 5886195 (1999-03-01), Tang et al.
patent: 5891917 (1999-04-01), Tang et al.
patent: 5912183 (1999-06-01), Comoglio et al.
patent: 5935993 (1999-08-01), Tang et al.
patent: 5958957 (1999-09-01), Andersen et al.
patent: 5965558 (1999-10-01), Mjalli et al.
patent: 5972978 (1999-10-01), Andersen et al.
patent: 5981569 (1999-11-01), App et al.
patent: 6037134 (2000-03-01), Margolis
patent: 6228986 (2001-05-01), Lanter et al.
patent: 6307090 (2001-10-01), Burke, Jr. et al.
patent: 2003/0114387 (2003-06-01), Castro Pineiro et al.
patent: WO 94/07913 (1994-04-01), None
patent: WO 95/11917 (1995-05-01), None
patent: WO 96/23813 (1996-08-01), None
patent: WO 97/08193 (1997-03-01), None
patent: WO 97/12903 (1997-04-01), None
patent: WO 98/17683 (1998-04-01), None
patent: WO 00/56760 (2000-09-01), None
patent: WO 00/73326 (2000-12-01), None
patent: WO 01/30325 (2001-05-01), None
patent: WO 02/16407 (2002-02-01), None
patent: WO 02/20525 (2002-03-01), None
patent: WO 02/40684 (2002-05-01), None
patent: WO 02/056837 (2002-07-01), None
R McKie. The Observer (2001). 4 pages.
GB Dermer. Bio/Technology (1994). p. 320.
P Puntervoll, et al. Nucleic Acids Research (2003) 31, pp. 3625-3630.
SH2-GRB2 ELM server. http://elm.eu.org/elmpages/Lig_sh2_grb2.html. Accessed Dec. 29, 2004.
J. Rudinger. In: Peptide Hormones. JA Parsons, ed. (1976) pp. 1-7.
T Pawson, et al. FEBS Letters. (2002) 513, pp. 2-10.
C Gorman, et al. Time (May 18, 1998) 151, 9 pages.
T Gura. Science (1997) 278, pp. 1041-1042.
SH2-STAT6 ELM server. http://elm.eu.org/elmpages/Lig_sh2_stat6.html. Accessed Dec. 29, 2004.
SH2-SRC ELM server. http://elm.eu.org/elmpages/Lig_sh2_src.html. Accessed Dec. 29, 2004.
SH2-PTP2 ELM server. http://elm.eu.org/elmpages/Lig_sh2_ptp2.html. Accessed Dec. 29, 2004.
SH2-STAT3 ELM server. http://elm.eu.org/elmpages/Lig_sh2_stat3.html. Accessed Dec. 29, 2004.
SH2-STAT5 ELM server. http://elm.eu.org/elmpages/Lig_sh2_stat5.html. Accessed Dec. 29, 2004.
Ye et al., “L-O-(2-Malonyl)tyrosine” A New Phosphotyrosyl Mimetic for the Preparation of Src Homology 2 Domain Inhibitory Peptides, J. Med. Chem. vol. 38, pp. 4270-4275, 1995.
Burke, Jr., et al., “4′-O-[2-(2-Fluoromalonyl)]-L-tyrosine: A Phosphotyrosyl Mimic for the Preparation of Signal Transduction Inhibitory Peptides”, J. Med. Chem., vol. 39, pp 1021-1027, Mar. 1, 1996.
Schoepfer et al.,“Structure-based Design of Peptidomimetic Ligands of Grb2-SH2 Domain”, Bioorganic & Medicinal Chemistry Letters 8, pp. 2865-2870, 1998.
Yao et al., “Potent Inhibition of Grb2 SH2 Domain Binding by Non-Phosphate-Containing Ligands”, J. Med. Chem., vol. 42, pp. 25-35, 1999.
Gay et al., “Effect of Potent and Selective Inhibitors of the Grb2 SH2 Domain on Cell Motility”, The Journal of Biological Chemistry, vol. 274, pp. 23311-23315, Aug. 13, 1999.
Schoepfer et al., “Highly Potent Inhibitors of the Grb2-SH2 Domain”, Bioorganic & Medicinal Chemistry Letters 9, pp. 221-226, 1999.
Burke, Jr., et al., Monocarboxylic-Based Phosphotyrosyl Mimetics in the Design of Grb2 SH2 Domain Inhibitors, Bioorganic & Medicinal Chemistry Letters 9, pp. 347-352, 1999.
Gilmer et al., “Peptide Inhibitors of src SH3-SH2-Phosphorprotein Interactions”, The Journal of Biological Chemistry, vol. 269, pp. 31711-31719, Dec. 16, 1994.
Charifson et al., “Peptide Ligands of pp60c-srcSH2 Domains: A Thermodynamic and Structural Study”, Biochemistry, vol. 36, pp. 6283-6293, 1997.
Liu et al., “Synthesis of L-2,3,5,6-Tetrafluoro-4-(Phosphonomethyl) Phenylalanine, a Novel Non-Hydrolyzable Phosphotyrosine Mimetic and L-4-(Phosphonodifluoromethyl) Phenylalanine”, Tetrahedron Letters, vol. 38, pp. 1389-1392, 1997.
Cleland, “The Meerwein Reaction in Amino Acid Synthesis. II. An Investigation of Twenty-one Substituted Anilines”, The Journal of Organic Chemistry, Vo., 34, pp. 744-747, Mar. 1969.
Gao et al., Inhibition of Grb2 SH2 Domain Binding by Non-Phosphate-Containing Ligands. 2. 4-(2-Malonyl)phenylalanine as a Potent Phosphotyrosyl Mimetic, J. Med. Chem., vol. 43, pp. 911-920, 2000.
Furet et al., Structure-Based Design and Synthesis of High Affinity Tripeptide Ligands of the Grb2-SH2 Domain, J. Med. Chem., vol. 41, pp. 3442-3449, 1998.
Tong et al., “Carboxymethyl-phenylalanine as a Replacement for Phosphotyrosine in SH2 Domain Binding”, The Journal of Biological Chemistry, vol. 273, pp. 20238-20242 Aug. 7, 1998.
Kim et al.,FEBS Lett,453, 174-178, 1999.
Tulasne et al., “The Multisubstrate Docketing Site of the MET Receptor is Dispensable for MET-mediated RAS Signaling and Cell Scattering”, Molecular Biology of the Cell, vol. 10, pp. 551-565, Mar. 1999.
Kim et al., “Dual Signaling Role of the Protein Tyrosine Phosphotase SHP-2 in Regulating Expression of Acute-Phase Proteins by Interleukin-6 Cytokine Receptors in Hepatic Cells”, Molecular and Cellular Biology, vol. 19, pp. 5326-5338, Aug. 1999.
Nguyen et al., “Association of the Multisubstrate Docking Protein Gab1 with the Hepatocyte Growth Factor Receptor Requires a Functional Grb2 Binding Site Involving Tyrosine 1356”, The Journal of Biologic
Burke, Jr. Terrence R.
Gao Yang
Voigt Johannes H.
Wei Chang-Qing
Campell Bruce R.
Kosar Andrew D.
Leydig , Voit & Mayer, Ltd.
The United States of America as represented by the Department of
LandOfFree
SH2 domain binding inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with SH2 domain binding inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and SH2 domain binding inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3513863